A carregar...
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up
Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). However, it remains unknown whether treatment should be continued until progression or discontinued in patients with good response. We present the history of a woman diagnosed with RCC in 19...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3851250/ https://ncbi.nlm.nih.gov/pubmed/24073932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-11-243 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|